A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions
Glomerulonephritis
Interventions
DRUG

Adrenocorticotrophic hormone ACTH

There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.

Trial Locations (1)

M5G2C4

University Health Network- Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

University Health Network, Toronto

OTHER